Atopix Therapeutics acquired by Chiesi Farmaceutici

21st November 2016

Atopix Therapeutics Limited, a UK biotechnology company with roots back to Oxford University, has been acquired by Italian pharmaceutical firm Chiesi Farmaceutici Spa.

Chiesi will acquire all shares, assets, and business of Abingdon-based Atopix. Considering regulatory and commercial milestones, the acquisition could exceed €75m. The deal includes OC459 – an orally-administered CRTh2 antagonist aimed at treating patients with severe asthma who have persistent airway eosinophilia. The drug is currently in Phase 2 trials.

Atopix Therapeutics is a spinout of a spinout, having been established by Oxagen Limited in 2012. Oxagen itself was first formed using research from Oxford University’s Wellcome Trust Centre for Human Genetics in 1997 to identify drug targets through genetics before refocusing its efforts on developing treatments for asthma.

For more information, please visit http://www.chiesigroup.com/en/ or http://www.atopixtherapeutics.co.uk.

Press release sign up